One of the first approaches to lower APP and Αβ involved antisense oligonucleotides (AONs) injected in different transgenic Alzheimer's disease mouse models that resulted in modest behavioral improvement by decreasing APP protein levels [16,17]. Here, PPIB is linked to Alzheimer disease.